[PDF][PDF] Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor …
AW Tolcher, M Mita, NJ Meropol… - Journal of Clinical …, 2007 - academia.edu
AW Tolcher, M Mita, NJ Meropol, M von Mehren, A Patnaik, K Padavic, M Hill, T Mays…
Journal of Clinical Oncology, 2007•academia.eduPurpose To assess the safety, pharmacokinetics, and preliminary evidence of antitumor
activity of mapatumumab (HGS-ETR1, TRM-1), a fully human agonist monoclonal antibody
directed to the tumor necrosis factor–related apoptosis-inducing ligand receptor-1 (TRAIL-
R1).
activity of mapatumumab (HGS-ETR1, TRM-1), a fully human agonist monoclonal antibody
directed to the tumor necrosis factor–related apoptosis-inducing ligand receptor-1 (TRAIL-
R1).
Purpose
To assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of mapatumumab (HGS-ETR1, TRM-1), a fully human agonist monoclonal antibody directed to the tumor necrosis factor–related apoptosis-inducing ligand receptor-1 (TRAIL-R1).
academia.edu